BLPH

Bellerophon Therapeutics, Inc. [BLPH] Stock Forecast

Q: What is Bellerophon Therapeutics, Inc. stock symbol ?

Bellerophon Therapeutics, Inc. is a US stock, located in Warren of Nj and trading under the symbol BLPH

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

BLPH Stock Summary

An RSI reading of 70 or higher indicates an overbought or overvalued condition.

BLPH has less than 1 year of cash runway

Top 10 Correlated ETFs

BLPH

Top 10 Correlated Stocks

BLPH

In the News

09:57 22 Mar 2023 BLPH

Here's Why Momentum in Bellerophon Therapeutics (BLPH) Should Keep going

Bellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

06:00 22 Mar 2023 BLPH

How to Find Cheap Penny Stocks to Make Money Trading

Use these tips for finding cheap penny stocks to buy The post How to Find Cheap Penny Stocks to Make Money Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

09:39 22 Mar 2023 BLPH

5 Hot Penny Stocks Exploding After News This Week

Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

02:18 22 Mar 2023 BLPH

Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size

Bellerophon's (BLPH) proposal to reduce the size of its ongoing phase III REBUILD study of INOpulse in fibrotic Interstitial Lung Disease gets accepted by the FDA. Stock up.

07:00 22 Mar 2023 BLPH

Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference

WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Naseem Amin, M.D., Chairman of Bellerophon's Board of Directors, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.

06:47 22 Mar 2023 BLPH

Bellerophon Therapeutics Stock (BLPH): Why The Price Jumped

The stock price of Bellerophon Therapeutics Inc (NASDAQ: BLPH) increased by 34.6% in the previous trading session. This is why it happened.

01:12 22 Mar 2023 BLPH

These Biotech Penny Stocks Exploded Today, Here's Why

Which biotech penny stocks are you watching right now? The post These Biotech Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

11:30 22 Mar 2023 BLPH

Bellerophon Therapeutics (BLPH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Bellerophon Therapeutics (BLPH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

08:30 22 Mar 2023 BLPH

Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021.

01:22 22 Mar 2023 BLPH

Why Entera Bio, Orphazyme, Bellerophon Are Moving Today

Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) are among the biggest biopharma movers Wednesday.

BLPH Financial details

Company Rating

Neutral

Market Cap

67.6M

Income

-14.82M

Revenue

Book val./share

0.78

Cash/share

1.19

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

29 Mar 2023

P/E

-4.63

Forward P/E

PEG

0.91

P/S

P/B

9.24

P/C

6.04

P/FCF

-4.32

Quick Ratio

2.19

Current Ratio

2.33

Debt / Equity

0.7

LT Debt / Equity

EPS (TTM)

-1.55

EPS next Y

EPS next Q

EPS this Y

-41.01%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

23.26%

SMA20

600%

SMA50

250%

SMA100

600%

Inst Own

9.69%

Inst Trans

-1.66%

ROA

-118%

ROE

-103%

ROC

-2.9%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

10.45M

Shs Float

5.89M

Target Price

52W Range

0.67-7.88

52W High

52W Low

RSI

Rel Volume

0.11

Avg Volume

2.27M

Volume

257.12K

Perf Week

5.35%

Perf Month

333.13%

Perf Quarter

598.06%

Perf Half Y

509.32%

Beta

0.346545

Volatility

0.35%, 2.55%

Prev Close

Price

7.19

Change

-6.01%

BLPH Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31
Revenue per share	0	0	0	0	0
Net income per share	0	0	0	-3.17	0
Operating cash flow per share	-6.06	-4.05	-2.87	-2.55	-2.4
Free cash flow per share	-6.06	-4.05	-2.87	-2.55	-2.4
Cash per share	12.25	4.35	2.19	6.1	2.6
Book value per share	-1	1.01	0.8	4.91	2.28
Tangible book value per share	-1	1.01	0.8	4.91	2.28
Share holders equity per share	-1	1.01	0.8	4.91	2.28
Interest debt per share	0	0	0.15	0.12	0.1
Market cap	100.49M	46.04M	23.62M	52.01M	29.46M
Enterprise value	71.67M	29.39M	16.07M	6.11M	5.68M
P/E ratio	0	0	0	-2.1	0
Price to sales ratio	0	0	0	0	0
POCF ratio	-6.38	-2.97	-1.83	-2.62	-1.29
PFCF ratio	-6.38	-2.97	-1.83	-2.62	-1.29
P/B Ratio	-38.74	11.94	6.58	1.36	1.36
PTB ratio	-38.74	11.94	6.58	1.36	1.36
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	0	0	0	-0.23	-0.28
EV to operating cash flow	-4.55	-1.9	-1.24	-0.31	-0.25
EV to free cash flow	-4.55	-1.9	-1.24	-0.31	-0.25
Earnings yield	0	0	0	-0.48	0
Free cash flow yield	-0.16	-0.34	-0.55	-0.38	-0.77
Debt to equity	-15.19	3.76	2.65	0.31	0.24
Debt to assets	1.07	0.79	0.73	0.24	0.2
Net debt to EBITDA	0	0	0	1.73	1.19
Current ratio	5.03	2.31	1.37	4.61	5.04
Interest coverage	0	0	0	-105.1	-4.03K
Income quality	0	0	0	0.8	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	0	0	0	18.71	0
ROIC	0	0	0	0.5	0
Return on tangible assets	0	0	0	-0.49	0
Graham Net	-2.92	0.56	0.08	4.56	2.05
Working capital	28.5M	9.86M	2.8M	37.65M	20.41M
Tangible asset value	-2.59M	3.86M	3.59M	38.25M	21.62M
Net current asset value	-3.82M	2.89M	865K	36.09M	20.2M
Invested capital	0	0	0.18	0.02	0.04
Average receivables	0	0	0	0	0
Average payables	3.33M	3.3M	2.93M	3.42M	2.46M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	0	0	0	-0.65	0
Capex per share	0	0	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric	2021-09-30	2021-12-31	2022-03-31	2022-06-30	2022-09-30
Revenue per share	0	0	0	0	0
Net income per share	-0.49	0	-0.59	-0.43	-0.53
Operating cash flow per share	-0.59	-0.42	-0.5	-0.38	-0.52
Free cash flow per share	-0.59	-0.42	-0.5	-0.38	-0.52
Cash per share	3.02	2.6	2.1	1.71	1.19
Book value per share	2.71	2.27	1.69	1.29	0.78
Tangible book value per share	2.71	2.27	1.69	1.29	0.78
Share holders equity per share	2.71	2.27	1.69	1.29	0.78
Interest debt per share	0.12	0.1	0.08	0.06	0.05
Market cap	38.6M	29.47M	22.53M	11.74M	10.4M
Enterprise value	11.02M	5.69M	3.3M	-4M	-516.46K
P/E ratio	-2.08	0	-1	-0.72	-0.51
Price to sales ratio	0	0	0	0	0
POCF ratio	-6.91	-7.41	-4.76	-3.2	-2.08
PFCF ratio	-6.91	-7.41	-4.76	-3.2	-2.08
P/B Ratio	1.5	1.36	1.39	0.96	1.4
PTB ratio	1.5	1.36	1.39	0.96	1.4
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-2.39	-1.34	-0.59	0.62	0.1
EV to operating cash flow	-1.97	-1.43	-0.7	1.09	0.1
EV to free cash flow	-1.97	-1.43	-0.7	1.09	0.1
Earnings yield	-0.12	0	-0.25	-0.35	-0.49
Free cash flow yield	-0.14	-0.13	-0.21	-0.31	-0.48
Debt to equity	0.21	0.24	0.34	0.44	0.7
Debt to assets	0.18	0.2	0.26	0.31	0.41
Net debt to EBITDA	5.98	5.59	3.42	2.43	2.18
Current ratio	5.8	5.04	3.69	3.12	2.33
Interest coverage	0	-854.6	-5.64K	-344.26	-108.85
Income quality	1.21	0	0.84	0.89	0.99
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	5.45	0	4.75	3.53	3.05
ROIC	0.18	0.14	0.28	0.24	0.44
Return on tangible assets	-0.15	0	-0.26	-0.23	-0.4
Graham Net	2.44	2.05	1.51	1.14	0.64
Working capital	24.59M	20.41M	14.95M	11.54M	6.88M
Tangible asset value	25.79M	21.62M	16.17M	12.28M	7.43M
Net current asset value	24.19M	20.2M	14.94M	11.54M	6.88M
Invested capital	0.04	0.04	0.05	0.05	0.05
Average receivables	0	0	0	0	0
Average payables	1.88M	1.24M	1.69M	2.1M	1.77M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.18	0	-0.35	-0.33	-0.68
Capex per share	0	0	0	0	0

BLPH Frequently Asked Questions

What is Bellerophon Therapeutics, Inc. stock symbol ?

Bellerophon Therapeutics, Inc. is a US stock , located in Warren of Nj and trading under the symbol BLPH

What is Bellerophon Therapeutics, Inc. stock quote today ?

Bellerophon Therapeutics, Inc. stock price is $7.19 today.

Is Bellerophon Therapeutics, Inc. stock public?

Yes, Bellerophon Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 2.27M
Market Capitalization 67.6M
Employee 20
CEO Mr. Peter Fernandes M. Pharm
Headquarters Warren,NJ,US
IPO Date 2015-02-13
Website https://bellerophon.com

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.